BridgeMD
New treatment option for Chronic Orofacial Pain
Official title Orofacial Pain Self-management: Personality Moderation Effect
ClinicalTrials.gov ID: NCT06932406
What this study is testing
- What it's testing
- The objective of this clinical trial is to study the effect of self-management on pain perception in patients with chronic orofacial pain and temporomandibular disorders (TMD) comparing it with the conventional treatment proposed by the TMD clinical practice guidelines. It also evaluates its effect on function and various psychosocial variables.
- Time commitment: about 10 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- The patient presents TMDs diagnosed according to the CD/TMD classification.
- Age between 18 and 65.
- Presence of pain in mandibular, temporal, facial, peri-auricular and/or auricular regions.
- Presence of chronic orofacial pain. Defined by the ICD-11 as orofacial pain or headache that occurs for more than two hours a day for 50% of the days...
- Orofacial pain is related to TMDs according to the International Classification of Headaches.
You likely can't join if
- Concomitant rheumatic systemic pathologies.
- History of trauma or recent surgical intervention in the head, face, neck or chest.
- Presence of intraoral infections or odontogenic pain.
- Headache of neuropathic origin (trigeminal neuralgia, Arnold neuralgia, etc.).
- Being receiving therapy (except rescue pharmacological therapy) for this disorder or pain.
- Cognitive impairment that prevents the follow-up of an educational program (determined through the MoCA questionnaire)
See the full eligibility criteria
- The patient presents TMDs diagnosed according to the CD/TMD classification.
- Age between 18 and 65.
- Presence of pain in mandibular, temporal, facial, peri-auricular and/or auricular regions.
- Presence of chronic orofacial pain. Defined by the ICD-11 as orofacial pain or headache that occurs for more than two hours a day for 50% of the days of the last three months.
- Orofacial pain is related to TMDs according to the International Classification of Headaches.
- Moderate pain intensity, corresponding to a weekly average of at least 30 mm on a 100 mm VAS (validated representation of moderate pain on the VAS scale = 31-54 mm)
- Concomitant rheumatic systemic pathologies.
- History of trauma or recent surgical intervention in the head, face, neck or chest.
- Presence of intraoral infections or odontogenic pain.
- Headache of neuropathic origin (trigeminal neuralgia, Arnold neuralgia, etc.).
- Being receiving therapy (except rescue pharmacological therapy) for this disorder or pain.
- Cognitive impairment that prevents the follow-up of an educational program (determined through the MoCA questionnaire)
The study team makes the final eligibility decision.
Where it's taking place
- Valencia, Valencia, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 10 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Valencia, Valencia, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.